Bibliographie – Centre PREFERE

À tous les âges de la vie, prendre soin

À tous les âges de la vie, prendre soin

Bibliographie – Centre PREFERE

  1. Navarria I, Usel M, Rapiti E, Neyroud-Caspar I, Pelte M-F, Bouchardy C, et al. Young patients with endometrial cancer: how many could be eligible for fertility-sparing treatment? Gynecol Oncol. sept 2009;114(3):448‑51.
  2. Lin KY, Miller DS, Bailey AA, Andrews SJ, Kehoe SM, Richardson DL, et al. Ovarian involvement in endometrioid adenocarcinoma of uterus. Gynecol Oncol. 14 juill 2015;
  3. Reed SD, Newton KM, Garcia RL, Allison KH, Voigt LF, Jordan CD, et al. Complex hyperplasia with and without atypia: clinical outcomes and implications of progestin therapy. Obstet Gynecol. août 2010;116(2 Pt 1):365‑73.
  4. Reed SD, Newton KM, Clinton WL, Epplein M, Garcia R, Allison K, et al. Incidence of endometrial hyperplasia. Am J Obstet Gynecol. juin 2009;200(6):678.e1-6.
  5. Koskas M, Azria E, Walker F, Luton D, Madelenat P, Yazbeck C. Progestin treatment of atypical hyperplasia and well-differentiated adenocarcinoma of the endometrium to preserve fertility. Anticancer Res. mars 2012;32(3):1037‑43.
  6. Koskas M, Yazbeck C, Walker F, Clouqueur E, Agostini A, Ruat S, et al. Fertility-sparing management of grade 2 and 3 endometrial adenocarcinomas. Anticancer Res. sept 2011;31(9):3047‑9.
  7. Gonthier C, Walker F, Luton D, Yazbeck C, Madelenat P, Koskas M. Impact of obesity on the results of fertility-sparing management for atypical hyperplasia and grade 1 endometrial cancer. Gynecol Oncol. avr 2014;133(1):33‑7.
  8. Gonthier C, Trefoux-Bourdet A, Luton D, Koskas M. [Fertility-sparing management of endometrial cancer and atypical hyperplasia]. Gynecol Obstet Fertil Senol. févr 2017;45(2):112‑8.
  9. Koskas M, Bendifallah S, Luton D, Daraï E, Rouzier R. Safety of uterine and/or ovarian preservation in young women with grade 1 intramucous endometrial adenocarcinoma: a comparison of survival according to the extent of surgery. Fertil Steril. nov 2012;98(5):1229‑35.
  10. Gonthier C, Trefoux-Bourdet A, Koskas M. Impact of Conservative Managements in Young Women With Grade 2 or 3 Endometrial Adenocarcinoma Confined to the Endometrium. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc. 10 févr 2017;
  11. Gonthier C, Luton D, Koskas M. [Extended endometrial ablation risks in the fertility sparing management of adenocarcinoma and atypical hyperplasia of the endometrium]. Gynécologie Obstétrique Fertil. mars 2015;43(3):185‑6.
  12. Gonthier C, Madelenat P, Walker F, Luton D, Koskas M. Hysteroscopic resection in the management of early-stage endometrial cancer: report of 2 cases and review of the literature. J Minim Invasive Gynecol. avr 2015;22(3):511‑2.
  13. Koskas M, Uzan J, Luton D, Rouzier R, Daraï E. Prognostic factors of oncologic and reproductive outcomes in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma: systematic review and meta-analysis. Fertil Steril. mars 2014;101(3):785‑94.
  14. Koskas M, Yazbeck C, Walker F, Delorme P, Azria E, Luton D, et al. [Fertility sparing management of endometrial adenocarcinoma and atypical hyperplasia: a literature review]. Bull Cancer (Paris). janv 2012;99(1):51‑60.
  15. Binder-Foucard F, Bossard N, Delafosse P, Belot A, Woronoff A-S, Remontet L, et al. Cancer incidence and mortality in France over the 1980-2012 period: solid tumors. Rev Dépidémiologie Santé Publique. avr 2014;62(2):95‑108.
  16. Purdie DM: Epidemiology of endometrial cancer. Reviews in Gynaecological Practice 3:217-220, 2003.
  17. Hasumi K, Sugiyama Y, Sakamoto K, Akiyama F. Small endometrial carcinoma 10 mm or less in diameter: clinicopathologic and histogenetic study of 131 cases for early detection and treatment. Cancer Med. déc 2013;2(6):872‑80.
  18. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. févr 1983;15(1):10‑7.
  19. Brun J-L, Descat E, Boubli B, Dallay D. [Endometrial hyperplasia: A review]. J Gynécologie Obstétrique Biol Reprod. oct 2006;35(6):542‑50.
  20. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of « untreated » hyperplasia in 170 patients. Cancer. 15 juill 1985;56(2):403‑12.
  21. Gitsch G, Hanzal E, Jensen D, Hacker NF. Endometrial cancer in premenopausal women 45 years and younger. Obstet Gynecol. avr 1995;85(4):504‑8.
  22. Farhi DC, Nosanchuk J, Silverberg SG. Endometrial adenocarcinoma in women under 25 years of age. Obstet Gynecol. déc 1986;68(6):741‑5.
  23. Randall TC, Kurman RJ. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol. sept 1997;90(3):434‑40.
  24. Westhoff C, Heller D, Drosinos S, Tancer L. Risk factors for hyperplasia-associated versus atrophy-associated endometrial carcinoma. Am J Obstet Gynecol. mars 2000;182(3):506‑8.
  25. Rodolakis A, Biliatis I, Morice P, Reed N, Mangler M, Kesic V, et al. European Society of Gynecological Oncology Task Force for Fertility Preservation: Clinical Recommendations for Fertility-Sparing Management in Young Endometrial Cancer Patients. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc. sept 2015;25(7):1258‑65.
  26. SGO Clinical Practice Endometrial Cancer Working Group, Burke WM, Orr J, Leitao M, Salom E, Gehrig P, et al. Endometrial cancer: a review and current management strategies: part II. Gynecol Oncol. août 2014;134(2):393‑402.
  27. Garuti G, Mirra M, Luerti M. Hysteroscopic view in atypical endometrial hyperplasias: A correlation with pathologic findings on hysterectomy specimens. J Minim Invasive Gynecol. août 2006;13(4):325‑30.
  28. Ørtoft G, Dueholm M, Mathiesen O, Hansen ES, Lundorf E, Møller C, et al. Preoperative staging of endometrial cancer using TVS, MRI, and hysteroscopy. Acta Obstet Gynecol Scand. mai 2013;92(5):536‑45.
  29. AlHilli MM, Dowdy SC, Weaver AL, St Sauver JL, Keeney GL, Mariani A, et al. Incidence and factors associated with synchronous ovarian and endometrial cancer: a population-based case-control study. Gynecol Oncol. avr 2012;125(1):109‑13.
  30. Lacey JV, Chia VM. Endometrial hyperplasia and the risk of progression to carcinoma. Maturitas. 20 mai 2009;63(1):39‑44.
  31. Gunderson CC, Fader AN, Carson KA, Bristow RE. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol. mai 2012;125(2):477‑82.